\
&
Contact us
Published on | 2 years ago
Programmes EICInnoBuyer is a coordination and support action funded under the European Innovation Council. The InnoBuyer consortium consists of F6S (Ireland), CIVITTA (Estonia) and TICBIOMED (Spain).
InnoBuyer aims to become a testing ground and benchmark towards the implementation of a demand-driven methodology that brings together Challengers (public and private organisations) and Solvers (notably European Innovation Council-supported SMEs), to jointly co-create innovative solutions, and speed-up the process leading to a concrete innovation procurement.
InnoBuyer programme will fund activities under four different actions. The Challengers selected to take part in the programme will get support from the InnoBuyer consortium to further define their unmet needs and translate them into a challenge (Action 1), that can be launched in a call for innovation suppliers/Solvers. Once the best Solver for each particular challenge gets selected (Action 2), Challengers and Solvers will co-create and pilot an innovative solution (Action 3). If by the end of the process the solution shows promising results, Challengers will receive support to launch an innovation procurement procedure (Action 4) for the wide adoption of the solution.
Currently the Call for Challengers is open and public and private organisations, legally established in any of the following countries can apply:
For all eligibility criteria check the Guidelines for Applicants for more information.
Call deadline is 31st of March 2023 at 17:00 CET. Up to 15 Challengers are expected to be funded, minimum 10 public Challengers and up to 5 private Challengers.
All information on the call, webinars, the application kit (guidelines, proposal form, model subgrant agreement etc.) and FAQs are available here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.